Drug intelligence / Profile preview

BCM-0718

Development stage: Preclinical
Lead developer: Biocidium Biopharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

BCM-0718 is a topical drug candidate under development by Biocidium Biopharmaceuticals for the treatment of pruritus. It is part of the company's dermatology pipeline and is formulated specifically for topical administration. Detailed information about its mechanism of action, molecular target, or chemical class has not been disclosed publicly. The primary indication currently listed for BCM-0718 is pruritus (itching)[1].

Beyond the preview

Go deeper on BCM-0718.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCM-0718.

Explore the full profile